Data Roundup: August 2024 Features Updates in CAR-T, mRNA Therapy, and Gamma ...
August 2024 saw significant data updates in CAR-T, mRNA, and GDT therapies for cancer, including a study recommending shorter monitoring after CAR T-cell therapy, BioNTech's mRNA therapy meeting primary endpoint in melanoma, long-term axi-cel data showing durable outcomes in lymphoma, Kiromic BioPharma's Deltacel generating favorable PFS data in NSCLC, and Orgenesis' CAR-T ORG-101 demonstrating efficacy and safety in ALL.
Related Clinical Trials
Reference News
August 2024 saw significant data updates in CAR-T, mRNA, and GDT therapies for cancer, including a study recommending shorter monitoring after CAR T-cell therapy, BioNTech's mRNA therapy meeting primary endpoint in melanoma, long-term axi-cel data showing durable outcomes in lymphoma, Kiromic BioPharma's Deltacel generating favorable PFS data in NSCLC, and Orgenesis' CAR-T ORG-101 demonstrating efficacy and safety in ALL.